Navigating Phase 3 Clinical Trials for Sepsis-Associated Acute Kidney Injury to Break the Mould in AKI
Time: 2:30 pm
day: Seminar Day
- From identifying patients to defining endpoints: analyzing a 650-patient phase 3 trial in AKI
- Surmounting 28-day mortality data and composite endpoints
- Redefining a new path to approval: what does the future of AKI drug development look like?